BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 24604006)

  • 1. Increased tyrosine hydroxylase expression accompanied by glial changes within the non-lesioned hemisphere in the 6-hydroxydopamine model of Parkinson's disease.
    Schlachetzki JC; Marxreiter F; Regensburger M; Kulinich A; Winner B; Winkler J
    Restor Neurol Neurosci; 2014; 32(4):447-62. PubMed ID: 24604006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
    Aponso PM; Faull RL; Connor B
    Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine cell morphology and glial cell hypertrophy and process branching in the nigrostriatal system after striatal 6-OHDA analyzed by specific sterological tools.
    Gomide V; Bibancos T; Chadi G
    Int J Neurosci; 2005 Apr; 115(4):557-82. PubMed ID: 15804725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
    Lee EY; Lee JE; Park JH; Shin IC; Koh HC
    Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease.
    Yuan H; Sarre S; Ebinger G; Michotte Y
    J Neurosci Methods; 2005 May; 144(1):35-45. PubMed ID: 15848237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model.
    Lazzarini M; Martin S; Mitkovski M; Vozari RR; Stühmer W; Bel ED
    Glia; 2013 Jul; 61(7):1084-100. PubMed ID: 23595698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of astroglial fibroblast growth factor-2 and microglia in the nigral 6-OHDA parkinsonism and a possible role of glucocorticoid hormone on the glial mediated local trophism and wound repair.
    Silva C; Fuxe K; Chadi G
    J Neural Transm Suppl; 2009; (73):185-202. PubMed ID: 20411778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuronal firing activity and gene expression changes in the subthalamic nucleus after transplantation of dopamine neurons in hemiparkinsonian rats.
    Rumpel R; Alam M; Klein A; Özer M; Wesemann M; Jin X; Krauss JK; Schwabe K; Ratzka A; Grothe C
    Neurobiol Dis; 2013 Nov; 59():230-43. PubMed ID: 23938762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Astroglial and microglial activation in the wistar rat ventral tegmental area after a single striatal injection of 6-hydroxydopamine.
    Rodrigues RW; Gomide VC; Chadi G
    Int J Neurosci; 2004 Feb; 114(2):197-216. PubMed ID: 14702208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraventricular injection of 6-hydroxydopamine results in an increased number of tyrosine hydroxylase immune-positive cells in the rat cortex.
    Wachter B; Caradonna S; Gittinger K; Schläger A; Küppers E
    Neuroscience; 2014 Nov; 280():99-110. PubMed ID: 25230286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoaminergic PET imaging and histopathological correlation in unilateral and bilateral 6-hydroxydopamine lesioned rat models of Parkinson's disease: a longitudinal in-vivo study.
    Molinet-Dronda F; Gago B; Quiroga-Varela A; Juri C; Collantes M; Delgado M; Prieto E; Ecay M; Iglesias E; Marín C; Peñuelas I; Obeso JA
    Neurobiol Dis; 2015 May; 77():165-72. PubMed ID: 25681534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential astroglial activation in 6-hydroxydopamine models of Parkinson's disease.
    Henning J; Strauss U; Wree A; Gimsa J; Rolfs A; Benecke R; Gimsa U
    Neurosci Res; 2008 Dec; 62(4):246-53. PubMed ID: 18824050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
    Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
    J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurotrophic effects of bone morphogenetic protein-7 in a rat model of Parkinson's disease.
    Harvey BK; Mark A; Chou J; Chen GJ; Hoffer BJ; Wang Y
    Brain Res; 2004 Oct; 1022(1-2):88-95. PubMed ID: 15353217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons.
    Iwakura Y; Piao YS; Mizuno M; Takei N; Kakita A; Takahashi H; Nawa H
    J Neurochem; 2005 May; 93(4):974-83. PubMed ID: 15857400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pirouetting pigs: A large non-primate animal model based on unilateral 6-hydroxydopamine lesioning of the nigrostriatal pathway.
    Christensen AB; Sørensen JCH; Ettrup KS; Orlowski D; Bjarkam CR
    Brain Res Bull; 2018 May; 139():167-173. PubMed ID: 29462643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurorescue effects of VEGF on a rat model of Parkinson's disease.
    Yasuhara T; Shingo T; Muraoka K; Kameda M; Agari T; Wen Ji Y; Hayase H; Hamada H; Borlongan CV; Date I
    Brain Res; 2005 Aug; 1053(1-2):10-8. PubMed ID: 16045899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats.
    Pellegrino D; Cicchetti F; Wang X; Zhu A; Yu M; Saint-Pierre M; Brownell AL
    J Nucl Med; 2007 Jul; 48(7):1147-53. PubMed ID: 17574972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.